Therapy to Watch: Huntington’s Disease PDUFA Date

UniQure has announced that the FDA has accepted its Biologics License Application (BLA) for ifezuntirgene inilparvovec, an investigational gene therapy for the treatment of Huntington’s disease. The FDA granted Priority Review and set a Prescription Drug User Fee Act (PDUFA) date of May 1, 2027.

 

https://www.uniqure.com/investors-media/press-releases?utm_content=388841363&utm_medium=social&utm_source=linkedin&hss_channel=lcp-37897480